AbbVie Inc ( NYSE:ABBV )
AbbVie Inc ( NYSE:ABBV ) quarterly sales were below Wall Street’s expectations on Friday, primarily due to lower-than-anticipated income from its popular cosmetic filler Juvederm and blockbuster anti-wrinkle injectable Botox. Due to this, AbbVie stock declined in the market.
Abbvie, situated in North Chicago, Illinois, had its stock price drop 2.6% to $149.45 before the opening bell.
The company’s $63 billion acquisition of Allergan’s aesthetic treatment portfolio, including Botox and Juvederm, is suffering from “temporary economic headwinds,” the pharmaceutical warned.
Analysts have been keeping an eye on AbbVie stock since its aesthetics business is more vulnerable to inflation and recession worries than the company’s other medications.
In July, AbbVie said that its Juvederm business had seen “glimpses of inflationary pressures” but that Botox had not yet been affected.
According to Refinitiv statistics, sales of Botox for aesthetic purposes came in at $637 million, which was below predictions of $640.17 million. In comparison, sales of Juvederm came in at $352 million, which was also below estimates of $360 million.
A 3.3% increase in net sales to $14.81 billion fell sho...
Click here to read the full article on PressReach.com .Subscribe to the PressReach RSS feeds:
- Featured News RSS feed
- Investing News RSS feed
- Daily Press Releases RSS feed
- Trading Tips RSS feed
- Investing Videos RSS feed
Follow PressReach on Twitter
Follow PressReach on TikTok
Follow PressReach on Instagram
Subscribe to us on Youtube